Cost-utility of minimally invasive therapies vs pharmacotherapy as initial therapy for benign prostatic hyperplasia: A Canadian healthcare payer perspective

Abstract

WVTT appears to be a cost-effective procedure and may be an appropriate first-line alternative to pharmacotherapy for patients with BPH and prostate volume less than 80 cm³ who seek faster improvement and no lifelong commitment to daily medications.